Skip to main content


Fig. 4 | BMC Infectious Diseases

Fig. 4

From: Immune responses in the treatment of drug-sensitive pulmonary tuberculosis with phenylbutyrate and vitamin D3 as host directed therapy

Fig. 4

Real-time RT-PCR assays of GADD34 and XBP1spl mRNAs from monocyte-derived-macrophages from TB patients receiving adjunct therapy with PBA and/or vitD3 or placebo (18/group) at week 0, week 4 and 8 after therapy. Data are normalized expression of GAD34 (a) and XBP1spl (b) mRNAs presented as means ± standard deviation. The results showed that PBA and vitD3 groups showed a significant reduction in expression of ER stress gene spliced XBP1 mRNA at week 8 compared to placebo

Back to article page